Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Drug

CStone Pharmaceuticals’ Sugemalimab Study Published in JCO for R/R ENKTL Treatment

Fineline Cube Mar 31, 2023

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, announced that the Journal of Clinical Oncology...

Medical Device

IceCure Medical Gains NMPA Approval for Cryoablation Technology in China

Fineline Cube Mar 31, 2023

Israel-based IceCure Medical (NASDAQ: ICCM) has announced that it has obtained regulatory approval from China’s...

Company Deals

SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal

Fineline Cube Mar 31, 2023

China-based SciNeuro Pharmaceuticals and Germany’s Secarna Pharmaceuticals GmbH & Co. KG have announced a research...

Company Deals

Beijing’s QL Bio Secures Tens of Millions in Funding for Proteomics Platform Upgrade

Fineline Cube Mar 30, 2023

QL Bio, a Beijing-based proteomics testing company, has reportedly secured tens of millions of renminbi...

Company Drug

ImmVira’s MVR-C5252 Receives NMPA Approval for Glioma Treatment Development

Fineline Cube Mar 30, 2023

China-based biotechnology company ImmVira has received approval from the National Medical Products Administration (NMPA) for...

Policy / Regulatory

Round 8 VBP Tender Results Announced with RMB 21.6 Billion Market

Fineline Cube Mar 30, 2023

The National Allied Procurement Office has issued an initial notification upon the completion of Round...

Company

Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials

Fineline Cube Mar 30, 2023

Global biotechnology company Harbour BioMed (HKG: 2142), with operations in the United States, the Netherlands,...

Company Drug

Janssen to Halt RSV Adult Vaccine Development, Impacting Phase III Trial

Fineline Cube Mar 30, 2023

Johnson & Johnson (J&J; NYSE: JNJ) subsidiary, Janssen, has announced its decision to terminate its...

Company

Luye Pharma Group Reports 15% Revenue Growth in 2022 Financial Results

Fineline Cube Mar 30, 2023

China-based Luye Pharma Group (HKG: 2186) has released its 2022 financial report, recording a total...

Company Drug

Pfizer’s Ritlecitinib Heads for Priority Review in China for Vitiligo Treatment

Fineline Cube Mar 30, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Pfizer’s (NYSE: PFE) ritlecitinib,...

Company Deals

Boston Scientific Partners with Scivita Medtech for Disposable Electronic Cholangioscope

Fineline Cube Mar 30, 2023

Boston Scientific Corporation (NYSE: BSX), a leading figure in the medical device industry, has announced...

Company Drug

Transcenta’s Osemitamab Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Mar 30, 2023

China-based biotechnology company Transcenta Holdings Ltd (HKG: 6628) has announced that its drug TST001 (osemitamab),...

Company Deals

CNBG Partners with China CDC to Strengthen Disease Prevention and Public Health

Fineline Cube Mar 30, 2023

China National Biotec Group Company Limited (CNBG) has announced a significant long-term partnership with the...

Company Drug

ImmuneOnco Achieves Full Enrollment in Phase II Study of IMM01 for CMML

Fineline Cube Mar 30, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced the successful completion of patient enrollment in its...

Company Medical Device

Shanghai Bio-Heart Begins RADIUS-HTN Study for Iberis RDN System in France

Fineline Cube Mar 29, 2023

China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced the first patient enrollment...

Company Deals

Shenzhen Hepalink’s OncoVent Secures Licensing Deal with Orient EuroPharma for Oregovomab

Fineline Cube Mar 29, 2023

Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its subsidiary, OncoVent, has...

Company Drug R&D

Kintor Pharmaceutical Realigns Funds from COVID-19 Studies to Other Pipeline Candidates

Fineline Cube Mar 29, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced a strategic change in the allocation of...

Company Deals

Pfizer Partners with HCRC to Support ‘Healthy China’ Initiative

Fineline Cube Mar 29, 2023

US pharmaceutical giant Pfizer (NYSE: PFE) has announced a strategic partnership agreement with China’s Health...

Company

Innovent Biologics Sees 6.7% Revenue Increase in 2022 Amidst R&D Growth and Product Expansion

Fineline Cube Mar 29, 2023

Biopharmaceutical company Innovent Biologics Inc., (HKG: 1801), has reported revenues of RMB 4.55 billion (USD...

Company

Astellas Pharma Executive Arrested in China on Spying Allegations

Fineline Cube Mar 29, 2023

A Japanese national and executive at the Chinese division of Tokyo-based Astellas Pharma Inc. (TYO:...

Posts pagination

1 … 566 567 568 … 688

Recent updates

  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.